Trial Profile

A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine [lamivudine/abacavir] (3TC) [Epzicom] to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) [emtricitabine/tenofovir disoproxil fumarate] [Truvada] in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; HIV protease inhibitors; Lamivudine/abacavir; Ritonavir
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms SWIFT
Sponsors Gilead Sciences

23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
12 Oct 2011 Results presented at the 13th European AIDS Conference.
20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com